Qiuyue Ding

Dr. Qiuyue Ding

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LCLinbin Chen
Linbin Chen
WLWanqian Liao
Wanqian Liao
JHJing Huang
Jing Huang
QDQiuyue Ding
Qiuyue Ding
JWJunwan Wu
Junwan Wu
XZXiaoshi Zhang
Xiaoshi Zhang
Background/Objectives: Natural killer (NK) cells play a crucial role in immune surveillance against melanoma, yet they frequently exhibit dysfunction in the tumor microenvironment. This study aims to establish an NK cell activation-related prognostic signature and identify potential druggable targets to overcome NK cell dysfunction. Methods: A prognostic signature was developed using the TCGA-SKCM cohort and validated across independent datasets. NK cell activation and cytotoxicity were evaluated in melanoma-NK-92MI co-culture systems via flow cytometry. Mechanistic studies employed Western blotting, co-immunoprecipitation, ELISA, and qRT-PCR. Single-cell RNA-seq data were used to analyze cell–cell communication. Results: A four-gene NK cell activation signature was identified and validated for prognostic significance across five independent melanoma datasets. Among the identified genes, cyclin B1 (CCNB1) emerged as a novel therapeutic target for overcoming NK cell resistance. In vivo, pharmacological inhibition of the CCNB1/Cyclin-dependent kinase 1 (CDK1) complex with RO-3306 significantly suppressed melanoma growth by enhancing NK cell infiltration and IFN-γ production. In vitro, CCNB1 knockdown in melanoma cells augmented NK-92MI activation, as evidenced by increased expression of CD69, CD107a, IFN-γ, and NKG2D, thereby improving NK cell-mediated cytotoxicity. Mechanistically, in melanoma cells, the CCNB1/CDK1 complex phosphorylates STAT3, activating the IL-6/STAT3 positive feedback loop, which upregulates PD-L1 and enables resistance to NK cell-mediated cytotoxicity. Beyond its role in immune evasion, CCNB1 also promoted melanoma invasiveness by inducing epithelial–mesenchymal transition (EMT) through the TGF-β-SMAD2/3 signaling. Conclusions: This study establishes CCNB1/CDK1 as a novel immunotherapeutic target and uncovers a new role for CDK1 inhibitors in enhancing NK cell function and suppressing melanoma progression.

31 March 2026 in Journal of Otolaryngology - Head & Neck Surgery
Verified
Journal Article
Open access
QDQiuyue Ding
Qiuyue Ding
JWJunwan Wu
Junwan Wu
YDYa Ding
Ya Ding
DLDandan Li
Dandan Li
XWXizhi Wen
Xizhi Wen
JLJingjing Li
Jingjing Li
Importance: The currently recommended postoperative adjuvant treatment for sinonasal mucosal melanoma (SNMM) (chemotherapy, optionally accompanied by local radiotherapy) has limited efficacy. Objective: We aimed to provide a potentially optimal adjuvant therapeutic strategy for patients with SNMM. Design: Retrospective cohort study. Setting: Our hospital’s cancer center. Participants: Seventy-nine patients with stage III/IV SNMM who underwent complete resection and received adjuvant radiotherapy between April 2012 and October 2022 were included in the study. Interventions: Patients were categorized into 2 groups based on different adjuvant medical regimens: a temozolomide/dacarbazine-based chemotherapy group (n = 44) and a temozolomide/dacarbazine chemotherapy plus PD-1 inhibitor group (n = 35). Main outcome measures: These included recurrence-free survival (RFS), distant metastasis-free survival (DMFS), failure patterns, and overall survival (OS). Results: The median follow-up duration was 56.8 (8.85-104.75) months in the chemotherapy group and 27.7 (14.53-40.87) months in the chemotherapy plus PD-1 inhibitor group, respectively. Relative to adjuvant chemoradiotherapy, the combination of additional PD-1 inhibitor significantly prolonged RFS (mRFS: 10.0 months vs 18.9 months; HR, 0.43; 95% CI, 0.25-0.75; P = .002), DMFS (mDMFS: 11.2 months vs 18.9 months; HR, 0.48; 95% CI, 0.27-0.84; P = .009), and OS (29.1 months vs NA; HR, 0.36; 95% CI, 0.17-0.77; P = .006) in patients with SNMM. Within a 2-year timeframe, patients in the chemotherapy plus PD-1 inhibitor group exhibited a lower regional recurrence rate than those in the chemotherapy group (0.0% vs 18.8%, P < .001). The 2-year OS rates in the adjuvant chemotherapy group and the chemotherapy combined with PD-1 inhibitor group were 54.5% versus 75.7%, respectively, while the corresponding 4-year OS rates were 20.9% and 62.4%. Conclusions and relevance: Surgery followed by adjuvant chemoradiotherapy and prompt initiation of PD-1 inhibitor therapy may improve local disease control in patients with SNMM.